A venture fund launched by Grey House Partners GP Inc. to invest in emerging and early-stage wellness, therapeutic and pharmaceutical companies around the globe. We have proudly taken the North Star pledge and believe in the importance of stewarding this sector in the right way.
“From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding”
Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience.
Our mission is to nurture the scientific advancement of mental, emotional, psychological and physical health by investing in alternative therapies, modalities, and sciences that are committed to optimizing our human experience.
We are committed to the development of pure, innovative and sustainable products and services that utilize technological innovation and the power of bioavailable plants that are often psychedelic in nature to help define a healthy future for our people and our planet.
Psychedelic medicine and related sustainable solutions for mental health and physical well being.
Noetic Fund will focus on finding teams with the skills, expertise, management experience, and governance structures in place to build world class companies.
Apollo Neuroscience improves your body’s resilience to stress, so you can focus, get to sleep, and stay energized.
Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.
Bexson Biomedical is developing new ketamine therapies for large-market and orphan indications.
COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Cybin is a mushroom life sciences company focused on psychedelic medicines and nutraceutical products.
Delix Therapeutics is the developer of small-molecule drug compounds intended to help provide treatment against mental disorders. The company is offering enantiomer compounds for neural plasticity promoting, enabling healthcare service providers to cure patients suffering from depression, anxiety, and post-traumatic stress disorders.
Diamond Therapeutics develops FDA-approved, psilocybin-based therapeutics that deliver patient benefits without undesired perceptual side effects.
Eleusis is dedicated to unlocking the potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, by mitigating and managing psychoactivity.
Eve Health Systems is a mental health services matching engine and practice management system, optimizing each piece of the experience for users seeking therapy.
Gilgamesh is developing the next generation of central nervous system drugs inspired by psychedelic medicines.
GHP Noetic Science-Psychedelic Pharma Inc. is a Capital Pool Corporation (CPC) formed to assist a future qualifying transaction to access the capital markets to fund its growth and expansion.
Merlyn Mind is building artificial intelligence that empowers society’s most important contributors.
MindMed discovers, develops, and deploys psychedelic inspired medicines to alleviate suffering and improve health.
Noetic Consciousness Inc. is a Capital Pool Corporation (CPC) formed to assist a future qualifying transaction to access the capital markets to fund its growth and expansion.
Numinus is an operating company at the forefront of addressing the growing prevalence of mental health issues and the desire for greater wellness.
PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.
Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications.
Psynergia Alliance is a Life Sciences platform that backs, builds and incubates best-in-class companies in the mental wellness space with a focus on psychedelic therapeutics.
Rythmia Life Advancement Center is an all-inclusive, medically licensed resort and wellness retreat in Costa Rica.
Sana Health is the world’s first pain and sleep management mask, aiding people around the world.
Tactogen is developing the next generation of empathogen medicines, gentler compounds within MDMA family for at-home use that can increase feelings of openness.
Terran aims to transform the lives of patients with neurological and psychiatric disorders through our next-generation therapeutics pipeline and imaging software device.
Vessel is the in-home wellness tracker that instantly and accurately uncovers what your body really needs.
6 years in venture capital, Silicon Valley, with focus on technology and software
20 years in mid-market M&A / Private Equity – c suite – private/publics – with top decile returns of 10x to 40x
BA in Economics from Queen’s University, Kingston
MBA from Trinity College, Dublin.
6 years leading VC- and PE-backed growth businesses: SVP Sales at Top Hat (10X growth in 4 years) and CEO at Globalfaces Direct (100% growth in 2 years)
6 years as a consulting leader with McKinsey & Company, including a fellowship to McKinsey’s Social Sector Office
MBA from Harvard Business School.
9 years at RBC Capital Markets in real estate banking, corporate credit, and derivative sales & trading
9 years at DGAM (acquired by The Carlyle Group) – Head of Marketing and Client Services, helped build AUM to $6.8B at peak
BA in Economics and Political Science from Columbia University.
20+ years in wholesale banking roles in New York, London, Toronto, Singapore and Bombay, covering syndicated & leveraged finance origination/structuring, global counterparty credit, and risk management at CIBC, BMO Capital Markets, TD Securities, and The Chase Manhattan Bank N.A.
MPA from Princeton University, BA in Economics (summa cum laude, Phi Beta Kappa) from Sewanee: The University of the South.
4 years working across startups, venture capital, and growth equity, including 2 years in investment analyst roles at XPV Water Partners (Toronto, water technology focus) and Khazanah Americas (San Francisco, healthcare technology focus)
BSc. in Science and Business (Biotechnology and Economics) from the University of Waterloo
Completed the CSC. AFM designation from Financial Modeling Institute.
5+ years research experience, from start-up market research to informing $3bn+ government spending envelopes
Founder of Psilocybin Alpha, leading resource for analysis of the emergent psychedelic sector
Consultant on numerous projects employing disruptive tech to solve societal issues
BSc Government (Harold Laski Scholar), the London School of Economics; with a year at UC Berkeley
Experienced in investment opportunity analysis in life sciences from TIAP (previously MaRS Innovation)
7+ years of research experience with 8 publications in peer-reviewed journals
Ph.D. (summa cum laude) in Biology from the Max Planck Society, Germany
M.Tech + B.Tech in Biotechnology (Minor in Chemistry) from Indian Institute of Technology Madras, India
Soccer player with Toronto City FC.
1 year in Science Policy and Capacity Building Division, UNESCO
M.Res. in Psychiatry seeking to validate cognitive biomarkers measuring decline and pharmacological intervention in Parkinson’s disease, Somerville College, University of Oxford
B.Sc. in. Anatomy and Cell Biology, McGill University.
CEO of Tactogen
30-year career spanning data science, preclinical pharmacology, clinical research, neuroscience, genomics and drug development
Bachelor’s degree in Philosophy and Post-doctoral Fellow at the University of Chicago
Ph.D. in Neuroscience from the University of California, Berkeley.
CEO of Pattern Pharma
30 years of experience founding and operating biotech ventures
DPhil in Physics from Christ Church College, University of Oxford
Bachelor’s in Mathematics from Trinity College, University of Toronto.
CIO of Apollo Neuroscience
Board-certified psychiatrist, neuroscientist, tech entrepreneur & inventor
Operates a clinical psychiatry practice and conducting research on the epigenetic regulation of trauma responses and recovery
Graduate degrees from Albany Medical College and psychiatric residency from Pittsburgh Medical Center.
16+ years investment banking and capital markets at firms including Bank of America Merrill Lynch, Deutsche Bank and Friedman, Billings, Ramsey
Managing Director at Centerboard Securities, a boutique capital advisory firm based in New York City
Former US Head of Capital Markets for $14B funds management business
MBA from Columbia Business School
BA in Semiotics from Brown University.
Chairman of Psychiatry at the Faculty of Medicine of the University of Debrecen
Residency training in Psychiatry both in Hungary (1986), and in the United States (1992)
Qualified psychopharmacologist (1987) of international merit
17 years of clinical and research experience in the United States.
Jody Levy is an artist, designer, director, entrepreneur, executive and investor
Jody is the founder, creative director and Chief Executive Officer of a handful of companies dedicated to empowering people to be as healthy and happy as possible.
Guggenheim Fellow (1986), Fellow of the Linnaean Society of London (1989), and Doctor Honoris Causa, from St. Lawrence, Canton, New York (2002)
Ph.D. from the Department of Comparative Religion Stockholm University (1989)
Master from Oslo University (1980)
B.A. from Madrid University (1972).
17+ years legal and finance at firms including Bank of America Merrill Lynch and Skadden Arps
Managing Director at Centerboard Securities, a boutique capital advisory firm based in New York City
Former Global Head of Capital Strategy for a $20b funds management business
Former editor of the Columbia Business Law Journal
Graduated from Oxford University (BA) and Columbia Law School (LL.M.).
9 years at Northwater Capital Management, as Managing Director – Head of Hedge Fund Investments
12 years at DGAM (acquired by The Carlyle Group) as Chief Investment Officer
Partner at The Carlyle Group and Chief Investment Officer of The Carlyle Liquid Markets Group.